Q2 EPS Estimates for Editas Medicine Cut by Zacks Research

Editas Medicine, Inc. (NASDAQ:EDIT) – Analysts at Zacks Research reduced their Q2 2026 EPS estimates for Editas Medicine in a research report issued to clients and investors on Monday, March 23rd. Zacks Research analyst Team now anticipates that the company will post earnings of ($0.34) per share for the quarter, down from their previous forecast of ($0.33). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine’s Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($0.35) EPS, Q2 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.36) EPS.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Monday, March 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.21. The company had revenue of $24.74 million during the quarter, compared to analysts’ expectations of $8.77 million. Editas Medicine had a negative net margin of 395.02% and a negative return on equity of 389.73%.

EDIT has been the subject of several other reports. Robert W. Baird set a $6.00 price objective on shares of Editas Medicine in a research report on Monday, March 9th. JonesTrading raised Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Tuesday, March 10th. TD Cowen reiterated a “buy” rating on shares of Editas Medicine in a research note on Monday, March 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a report on Wednesday, January 21st. Finally, Chardan Capital restated a “buy” rating and issued a $3.50 price target on shares of Editas Medicine in a research note on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.30.

Editas Medicine Stock Performance

Shares of EDIT opened at $2.25 on Wednesday. The firm has a market cap of $220.21 million, a P/E ratio of -1.19 and a beta of 2.16. Editas Medicine has a 52 week low of $0.91 and a 52 week high of $4.54. The firm’s 50-day simple moving average is $2.09 and its 200 day simple moving average is $2.56.

Institutional Trading of Editas Medicine

Large investors have recently modified their holdings of the stock. Captrust Financial Advisors bought a new position in shares of Editas Medicine in the second quarter worth $26,000. StoneX Group Inc. bought a new stake in Editas Medicine during the fourth quarter worth about $33,000. Victory Capital Management Inc. bought a new stake in Editas Medicine during the third quarter worth about $36,000. Sei Investments Co. acquired a new stake in Editas Medicine during the third quarter worth about $46,000. Finally, Baader Bank Aktiengesellschaft acquired a new stake in Editas Medicine during the third quarter worth about $50,000. 71.90% of the stock is owned by institutional investors and hedge funds.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.